CL2018002539A1 - Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos - Google Patents

Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos

Info

Publication number
CL2018002539A1
CL2018002539A1 CL2018002539A CL2018002539A CL2018002539A1 CL 2018002539 A1 CL2018002539 A1 CL 2018002539A1 CL 2018002539 A CL2018002539 A CL 2018002539A CL 2018002539 A CL2018002539 A CL 2018002539A CL 2018002539 A1 CL2018002539 A1 CL 2018002539A1
Authority
CL
Chile
Prior art keywords
acid
hydroxyisoxazol
ethoxymethyl
biphenyl
fluoro
Prior art date
Application number
CL2018002539A
Other languages
English (en)
Spanish (es)
Inventor
Melissa Fleury
Venkat R Thalladi
Gene Timothy Fass
Miroslav Rapta
Adam D Hughes
Michael Simeone
R Michael Baldwin
David L Bourdet
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58387911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018002539(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2018002539A1 publication Critical patent/CL2018002539A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CL2018002539A 2016-03-08 2018-09-05 Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos CL2018002539A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305393P 2016-03-08 2016-03-08
US201662346336P 2016-06-06 2016-06-06

Publications (1)

Publication Number Publication Date
CL2018002539A1 true CL2018002539A1 (es) 2018-10-26

Family

ID=58387911

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002539A CL2018002539A1 (es) 2016-03-08 2018-09-05 Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos

Country Status (30)

Country Link
US (6) US10100021B2 (cg-RX-API-DMAC7.html)
EP (1) EP3408260B1 (cg-RX-API-DMAC7.html)
JP (2) JP7306828B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220035991A (cg-RX-API-DMAC7.html)
CN (1) CN108779084A (cg-RX-API-DMAC7.html)
AU (1) AU2017229466C1 (cg-RX-API-DMAC7.html)
CA (1) CA3015505C (cg-RX-API-DMAC7.html)
CL (1) CL2018002539A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018010568A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124397T1 (cg-RX-API-DMAC7.html)
DK (1) DK3408260T3 (cg-RX-API-DMAC7.html)
ES (1) ES2880123T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211169T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055546T2 (cg-RX-API-DMAC7.html)
IL (1) IL261244B (cg-RX-API-DMAC7.html)
LT (1) LT3408260T (cg-RX-API-DMAC7.html)
MX (1) MX377177B (cg-RX-API-DMAC7.html)
MY (1) MY198185A (cg-RX-API-DMAC7.html)
PH (1) PH12018501876A1 (cg-RX-API-DMAC7.html)
PL (1) PL3408260T3 (cg-RX-API-DMAC7.html)
PT (1) PT3408260T (cg-RX-API-DMAC7.html)
RS (1) RS62172B1 (cg-RX-API-DMAC7.html)
RU (1) RU2756223C2 (cg-RX-API-DMAC7.html)
SA (1) SA518392325B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201807591VA (cg-RX-API-DMAC7.html)
SI (1) SI3408260T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100434T1 (cg-RX-API-DMAC7.html)
TW (1) TWI731943B (cg-RX-API-DMAC7.html)
WO (1) WO2017156009A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805840B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100021B2 (en) 2016-03-08 2018-10-16 Theravance Biopharma R&D Ip, Llc Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
JP7316449B2 (ja) * 2019-09-20 2023-07-27 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用
KR102485499B1 (ko) * 2022-07-15 2023-01-09 오가노이드사이언스 주식회사 신장 질환의 치료 또는 예방용 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
US4206232A (en) 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4906615A (en) 1980-12-18 1990-03-06 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4939261A (en) 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
EP0225292A3 (en) 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
KR880007441A (ko) 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
FR2623498B1 (fr) 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
GB8820844D0 (en) 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5599951A (en) 1989-09-15 1997-02-04 Societe Civile Bioprojet Amino acid derivatives, the process for their preparation and their applications to therapy
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
US6660756B2 (en) 2001-03-28 2003-12-09 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20070204367A1 (en) 2006-02-17 2007-08-30 Stanislaw Flasinski Chimeric regulatory sequences comprising introns for plant gene expression
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CA2674291C (en) 2007-01-12 2015-11-24 Novartis Ag New process
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
AR070176A1 (es) 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
EP3048100A1 (en) 2009-05-28 2016-07-27 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
ES2523734T3 (es) * 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2550485T3 (es) 2010-01-22 2015-11-10 Novartis Ag Intermedios de inhibidores de la endopeptidasa neutra y método de preparación de los mismos
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
HRP20151115T1 (en) 2010-12-15 2015-11-20 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
BR112013014952A2 (pt) 2010-12-15 2017-05-30 Theravance Inc inibidores de neprilisina
EP2675795B1 (en) * 2011-02-17 2016-04-20 Theravance Biopharma R&D IP, LLC Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012154249A1 (en) 2011-02-17 2012-11-15 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
EP2714660B1 (en) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
RS55967B1 (sr) 2012-06-08 2017-09-29 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
CA2873328A1 (en) 2012-06-08 2013-12-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
SMT201700134T1 (it) * 2012-08-08 2017-05-08 Theravance Biopharma R&D Ip Llc Inibitori della neprilisina
KR101811549B1 (ko) * 2013-06-19 2017-12-26 에프. 호프만-라 로슈 아게 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
CN105992763A (zh) * 2014-01-30 2016-10-05 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
US10100021B2 (en) 2016-03-08 2018-10-16 Theravance Biopharma R&D Ip, Llc Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

Also Published As

Publication number Publication date
US11718591B2 (en) 2023-08-08
SI3408260T1 (sl) 2021-08-31
AU2017229466B2 (en) 2020-08-13
CA3015505A1 (en) 2017-09-14
WO2017156009A1 (en) 2017-09-14
US20200157061A1 (en) 2020-05-21
BR112018068170A2 (pt) 2019-01-29
MX2018010727A (es) 2019-01-24
MY198185A (en) 2023-08-09
CA3015505C (en) 2024-03-05
US11230536B2 (en) 2022-01-25
HUE055546T2 (hu) 2021-12-28
US10472335B2 (en) 2019-11-12
JP7306828B2 (ja) 2023-07-11
ZA201805840B (en) 2019-07-31
KR20220035991A (ko) 2022-03-22
EP3408260A1 (en) 2018-12-05
JP2022017433A (ja) 2022-01-25
ES2880123T3 (es) 2021-11-23
SMT202100434T1 (it) 2021-09-14
RU2018135072A3 (cg-RX-API-DMAC7.html) 2020-10-15
RU2018135072A (ru) 2020-04-08
PH12018501876A1 (en) 2019-01-28
TW201741290A (zh) 2017-12-01
PT3408260T (pt) 2021-07-23
LT3408260T (lt) 2021-07-26
AU2017229466A1 (en) 2018-09-13
IL261244A (en) 2018-10-31
US20170275259A1 (en) 2017-09-28
EP3408260B1 (en) 2021-05-05
PL3408260T3 (pl) 2021-11-08
SG11201807591VA (en) 2018-10-30
HRP20211169T1 (hr) 2021-11-12
CO2018010568A2 (es) 2018-10-22
AU2017229466C1 (en) 2021-02-11
RU2756223C2 (ru) 2021-09-28
CN108779084A (zh) 2018-11-09
DK3408260T3 (da) 2021-08-02
KR20180114225A (ko) 2018-10-17
JP2019509286A (ja) 2019-04-04
US20240327360A1 (en) 2024-10-03
US20190002416A1 (en) 2019-01-03
US20210061776A1 (en) 2021-03-04
US10752599B2 (en) 2020-08-25
US12351561B2 (en) 2025-07-08
US10100021B2 (en) 2018-10-16
CY1124397T1 (el) 2022-07-22
RS62172B1 (sr) 2021-08-31
MX377177B (es) 2025-03-07
SA518392325B1 (ar) 2022-08-03
TWI731943B (zh) 2021-07-01
US20220242836A1 (en) 2022-08-04
IL261244B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
ECSP15014941A (es) Compuestos antivíricos para el vsr
MX2017007426A (es) Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2015004771A (es) Metodos para tratar cancer.
MX2016013052A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
WO2015120237A3 (en) 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CO2017008115A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico
CL2020000334A1 (es) Formas cristalinas de 2-[(2,4-diclorofenil)metil]-4,4-dimetil-isoxazolidin-3-ona.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2018002539A1 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
MX2018013729A (es) Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.
CL2022001736A1 (es) Nuevos compuestos farmacéuticos
CL2017002229A1 (es) Inhibidores de bace1.